Skip Navigation Archive: U.S. Department of Health and Human Services www.hhs.gov
Archive: Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

New Community-based Study Tracks Rates of Antibiotic-resistant Bacteria in Massachusetts Children

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

New vaccine reduces strains of bacteria most likely to cause severe infections

Press Release Date: October 6, 2003

A new study of 16 Massachusetts communities found that 8 percent of children under age 7 carry antibiotic-resistant S. pneumoniae, a bacterium commonly found in healthy children but which presents a low risk of illness to them. While this rate is much higher than would have been seen a decade ago, a new vaccine is reducing the presence of strains of the bacterium that can cause significant infection, according to the Agency for Healthcare Research and Quality.

Overall, researchers found that 190 (26 percent) of the children tested were carrying a strain of S. pneumoniae, and further testing of 166 of the samples indicated that many were resistant to a range of commonly used antibiotics. Since S. pneumoniae is a major cause of meningitis, bloodstream infections, and pneumonia as well as ear and sinus infections every year in children under age 5, the risk to communities is that when serious, but rare, infections do develop, antibiotic-resistant strains make the illnesses harder to treat.

Specifically, 33 percent of the tested samples were at least somewhat resistant to penicillin, 31 percent to trimethoprim/sulfamethoxizole, 22 percent to erythromycin, and 3 percent to clindamycin. In addition, 22 percent were resistant to at least three antibiotics. Children in group child care were four times more likely to carry the antibiotic-resistant bacterium. Those who had recently used antibiotics or who had a current respiratory infection were also more likely to carry resistant strains. Resistance among S. pneumoniae has been rising over the past decade throughout the United States, but infections with this bacterium are still effectively treated with available antibiotics.

This study, published in the October issue of Pediatrics, is the first of its kind performed after introduction of a new vaccine to protect children from the seven most invasive strains of S. pneumoniae, which cause more than 80 percent of the serious infections. The rate of children who carried an antibiotic resistant strain was the same in children who had received the vaccine and those who had not. However, immunized children were less likely to carry one of the seven more invasive strains and are at lower risk of contracting a serious disease.

The authors, led by Jonathan Finkelstein, M.D., M.P.H., and his colleagues at the Department of Ambulatory Care and Prevention, a unique research and teaching collaboration between Harvard Pilgrim Health Care and Harvard Medical School, caution that the study, conducted only 9 months after the vaccine was introduced, may not reflect the ultimate benefit of the vaccine as more children in the population are immunized.

Dr. Finkelstein and his colleagues analyzed background information from parents and nasal swab samples from 742 children in 16 geographically diverse communities in Massachusetts between March and May 2001. The children tested were visiting their pediatricians for a variety of reasons, including colds, ear infections, and routine well care.

Beginning in 2000, the American Academy of Pediatrics recommended that all children 23 months and younger be immunized routinely with a new vaccine against the seven strains of S. pneumoniae that cause most of the serious infections from this bacterium. Dr. Finkelstein and his colleagues conclude that continued monitoring of antibiotic resistance is warranted both in the strains of bacteria covered by the vaccine as well as those not covered. "The use of this vaccine in combination with recently reported decreases in antibiotic prescribing are two important steps in protecting children from serious antibiotic-resistant infections," he said.

Editor's Notes:

Last month, HHS joined a consortium of major national health organizations to launch a new national campaign to educate consumers about the use of antibiotics. Officials stressed that antibiotics are an ineffective treatment for viruses, such as those that cause colds and flu, and that inappropriate antibiotic use—particularly among children—is contributing to an alarming growth of global antibiotic resistance. More information about this campaign and antibiotic resistance is available at http://www.cdc.gov/drugresistance/community/.

For interviews with Dr. Finkelstein, please contact Harvard Medical School's Office of Public Affairs at (617) 432-0442 or public_affairs@hms.harvard.edu.

For more information, please contact AHRQ Public Affairs: Karen Migdail (301) 427-1855 (KMigdail@ahrq.gov; Farah Englert (301) 427-1865 (FEnglert@ahrq.gov).


 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care